Tesamorelin: The Approved GHRH Analog

By Evan Marsh, EditorUpdated August 7, 2026Sources: Phase 3 trials, JAMA, The Lancet HIV, FDA label

Of every growth-hormone-axis peptide sold today, tesamorelin is the one with the least to hide: a full Phase 3 program, an FDA approval that still stands (Egrifta, 2010), a label you can read, and randomized trials in liver fat, muscle quality and cognition on top. The catch sits in the fine print — all of that approval-grade evidence was generated in people with HIV-associated lipodystrophy, and the approved indication is exactly that narrow. Everything else is extrapolation, and this page keeps the two separate.

How tesamorelin works

Tesamorelin is human GHRH(1-44) with a trans-3-hexenoyl group attached at the N-terminus. The modification protects the peptide from rapid enzymatic breakdown while leaving receptor binding intact, so it does what GHRH does — stimulate pituitary release of the body's own growth hormone in pulses — with pharmacokinetics that support once-daily injection. Feedback regulation stays intact, the property that separates every GHRH analog from injecting growth hormone directly. GH then drives lipolysis preferentially in visceral fat, which is why the clinical program targeted abdominal fat accumulation.

The evidence

Visceral fat — the approval dataset

Two multicenter Phase 3 trials in HIV-associated lipodystrophy showed significant reductions in visceral adipose tissue versus placebo, with improvements in patient- reported belly appearance distress. The pooled analysis of both trials carried Egrifta to approval in 2010. Two honest footnotes belong next to that result. The long-term extensions showed that visceral fat reaccumulates after discontinuation — tesamorelin manages fat while you inject it, it does not reset anything. And subcutaneous fat is largely unaffected: this is a visceral-fat drug, not a general weight-loss drug. For compounds that actually move total body weight, see the weight-loss ranking.

Liver fat — the strongest recent data

A randomized JAMA trial extended the finding to liver fat, and a 12-month double-blind trial in HIV-associated NAFLD made it concrete: a 37% relative reduction in hepatic fat fraction versus placebo, with 35% of treated participants reaching normal liver fat against 4% on placebo. Glucose and HbA1c did not worsen over the year. This is the most clinically interesting corner of the tesamorelin literature — and it is still an HIV-population result.

Muscle and cognition — smaller signals

An imaging substudy found decreased muscle fat and increased muscle area in adults with HIV. Separately, a 20-week randomized trial in adults with mild cognitive impairment and healthy older adults — run with tesamorelin — reported improved executive function. Both are single studies; neither is an approved use; neither has been replicated at scale.

How to read all of this: every controlled result above comes from populations with a diagnosed condition — lipodystrophy, NAFLD, cognitive impairment. No registrational trial has tested tesamorelin for cosmetic fat loss in healthy adults. The biology plausibly transfers; the effect sizes may not, and nobody has measured them.

Side effects and monitoring

Injection-site reactions — redness, itching, bruising; the most common complaint in trials.
Joint aches, muscle stiffness, fluid retention — classic GH-axis effects, usually dose-related.
Glucose — GH reduces insulin sensitivity, so the label requires monitoring. A dedicated 12-week randomized trial in type 2 diabetes found no deterioration in glycemic control; reassuring, but short.
IGF-I elevation — the label calls for periodic IGF-I monitoring; sustained elevation is the mechanism behind the malignancy caution that applies to the whole GH class.

The label contraindicates use in active malignancy, pregnancy, and disruption of the hypothalamic-pituitary axis. Our safety overviewcovers how these class risks compare across compounds.

Dosing references

Context	Amount	Frequency	Basis
Egrifta (approved label)	2 mg	Once daily, subcutaneous	Phase 3 trials
Research-market practice	1–2 mg	Once daily	Mirrors the label

Vial	Water	Concentration	1 mg	2 mg	Doses (2 mg)
10 mg	2 ml	5,000 mcg/ml	20 units	40 units	5
10 mg	2.5 ml	4,000 mcg/ml	25 units	50 units	5

Peptide preset

Peptide in vial (mg)

Bacteriostatic water added (ml)

Desired dose (mcg)

—

Concentration (mcg / ml)

—

Volume to draw (ml)

—

Units on U-100 insulin syringe

—

Doses per vial

Draw to this mark on a 1 ml U-100 insulin syringe

Formula: concentration = peptide (mcg) ÷ water (ml). Volume = dose ÷ concentration. One unit on a U-100 insulin syringe = 0.01 ml. Values are for laboratory reference only.

Regulatory status

2010 — FDA approved Egrifta for excess abdominal fat in HIV-associated lipodystrophy. The approval stands; current formulations are marketed as EGRIFTA SV and EGRIFTA WR.
Prescription reality — brand Egrifta is expensive and insurance-gated to the HIV indication, which is what pushes off-label interest toward compounding and the research market.
WADA — prohibited for tested athletes under S2.2, which names GHRH analogues including tesamorelin.

Research on Tesamorelin

12 records in our research database, classified by evidence type:

HumanBody composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trialsBadran AS et al. · Obesity Research & Clinical Practice, 2026
HumanEffects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trialStanley TL et al. · The Lancet HIV, 2019
HumanThe Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIVAdrian S et al. · Journal of Frailty & Aging, 2019
HumanSafety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trialClemmons DR et al. · PLOS ONE, 2017

Browse all Tesamorelin research →

Recommended supplier · affiliate partner

Tesamorelin — 10 mg — American Peptides

Sold as lyophilized vials for research use, including a tesamorelin + ipamorelin blend. At milligram doses, verify the batch COA covers the full labeled mass — HPLC and mass-spec documentation per batch.

Check Price →

We may earn a commission if you buy through this link (at no extra cost to you). Sold for research purposes only.

Frequently asked questions

What is tesamorelin used for?

Its one approved use is reducing excess abdominal fat in HIV-associated lipodystrophy, as Egrifta. Off-label and gray-market use targets visceral fat and liver fat generally, extrapolating from trials run in people with HIV. It is the only GHRH analog with a current FDA approval.

Does tesamorelin reduce belly fat?

In its Phase 3 trials in HIV-associated lipodystrophy it produced significant reductions in visceral adipose tissue versus placebo — and the extension studies showed the fat returns after stopping. Whether the same magnitude applies to people without HIV has not been established in a registrational trial.

What is the tesamorelin dose?

The approved Egrifta dose is 2 mg injected subcutaneously once daily. Research-market protocols generally mirror it. Trials of the current formulations use the equivalent exposure at smaller injection volumes.

Does tesamorelin affect blood sugar?

Growth hormone axis drugs can reduce insulin sensitivity, so the label requires glucose monitoring. A dedicated 12-week randomized trial in people with type 2 diabetes found no change in glycemic control — reassuring, but short, and monitoring is still the standard.

Tesamorelin vs sermorelin — what is the difference?

Both are GHRH analogs. Tesamorelin carries a trans-hexenoyl modification that stabilizes it against enzymatic breakdown, supports once-daily dosing, and carried a full Phase 3 program to FDA approval. Sermorelin is the unmodified GHRH fragment: shorter-acting, formerly approved for children, never proven in adults for body composition.

Sources

Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 2007;357(23):2359–70. PubMed
Falutz J et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS, 2008;22(14):1719–28. PubMed
Falutz J et al. Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. JAIDS, 2010;53(3):311–22. PubMed
Falutz J et al. Effects of tesamorelin in HIV-infected patients with excess abdominal fat: a pooled analysis of two Phase 3 trials with safety extension data. Journal of Clinical Endocrinology & Metabolism, 2010. PubMed
Stanley TL et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA, 2014;312(4):380–389. PubMed
Stanley TL et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. The Lancet HIV, 2019;6(12):e821–e830. PubMed
Baker LD et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Archives of Neurology, 2012;69(11):1420–1429. PubMed
Adrian S et al. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. Journal of Frailty & Aging, 2019;8(3):154–159. PubMed
Clemmons DR et al. Safety and metabolic effects of tesamorelin in patients with type 2 diabetes: a randomized, placebo-controlled trial. PLOS ONE, 2017;12(6):e0179538. PubMed
Badran AS et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin in HIV-associated lipodystrophy: a meta-analysis of randomized controlled trials. Obesity Research & Clinical Practice, 2026;20(1):2–12. PubMed
EGRIFTA SV (tesamorelin) prescribing information. DailyMed label
World Anti-Doping Agency. Prohibited List 2026, section S2.2 — GHRH and its analogues. WADA Prohibited List

Related guides

Research use only. Tesamorelin sold outside a prescription is not approved for human use. This page summarizes published research and is not medical advice.